Addyi Cost in New York 2026: Price, Insurance, Medicaid, and Compounding Options

Flibanserin, sold under the brand name Addyi (Sprout Pharmaceuticals), is an oral tablet approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not a hormone and it is not related to sildenafil-type erectile dysfunction drugs. This page covers what is reliably known about accessing flibanserin in New York and what cost and coverage details change often enough that they need to be checked at the time you need them, rather than trusted from any single article.

Direct answer: Addyi is FDA-approved, requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program because of an alcohol interaction, and is dispensed as a brand-only tablet in the United States with no FDA-approved generic as of this writing. New York Medicaid and many commercial New York plans can cover it, typically with prior authorization, but exact copays, prior authorization timelines, and cash prices change often and must be confirmed with the specific plan or pharmacy at the time of fill, not assumed from a published price list.

What flibanserin is and how it's regulated

Flibanserin was approved by the FDA on August 18, 2015, for HSDD in premenopausal women. Because of a documented interaction with alcohol that can cause severe hypotension and syncope, the FDA requires prescribers, pharmacies, and patients to enroll in the Addyi REMS program before a prescription can be dispensed. The drug carries a boxed warning against alcohol use, and against use with moderate or strong CYP3A4 inhibitors, because of the same hypotension risk. These are FDA label-level facts and are the most stable claims on this page. (FDA product and REMS information: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526)

There is no FDA-approved generic flibanserin tablet at this time. That status can change, and readers should check the FDA's Orange Book or the label page above for the current status before assuming otherwise.

What the retail price actually is

Addyi has been reported publicly as a high-cost brand-only specialty medication, with list prices in the hundreds of dollars per month range. This draft does not carry forward a specific dollar figure as fact, because no verifiable, current source was available at the time of writing to confirm an exact 2026 list price, cash price, or discount-card price for New York pharmacies specifically. Cash and list prices for brand specialty drugs change without notice and differ by pharmacy chain, so any number quoted online, including numbers that may have appeared in earlier drafts of this page, should be treated as unverified until confirmed directly with a New York pharmacy or the manufacturer at the time of fill.

Does New York Medicaid cover Addyi?

New York Medicaid formularies can include coverage for FDA-approved medications with prior authorization, and flibanserin's premenopausal HSDD indication is the kind of narrow, symptom-specific indication that typically triggers a prior authorization requirement rather than automatic exclusion. That said, this draft does not have a verified, current New York Medicaid formulary listing or prior authorization turnaround time to cite, so specific claims about approval criteria, processing days, or the exact eMedNY workflow have been removed rather than repeated from an unverified source. Prescribers and patients should confirm current prior authorization criteria directly through the eMedNY clinical policy pages or the patient's Medicaid Managed Care organization before assuming a specific timeline or requirement.

Does commercial insurance in New York cover Addyi?

Commercial insurers commonly place specialty and sexual-health medications on higher formulary tiers with step therapy or prior authorization requirements, and it is plausible that specific New York carriers apply this approach to flibanserin. However, this draft does not have a verified, dated formulary excerpt from any named New York insurer, so specific insurer names, tier placements, and step-therapy criteria from an earlier version of this page have been removed as unverified rather than presented as current fact. The reliable path for a reader is to check the specific plan's own drug formulary tool or call member services, since formulary tiers are reviewed and changed on an annual or more frequent basis.

Are there manufacturer savings programs?

Manufacturer copay assistance programs for brand specialty drugs are common in the United States and typically exclude patients covered by Medicaid, Medicare, or other government-funded insurance, consistent with standard anti-kickback rules that apply to copay cards generally. Whether Sprout Pharmaceuticals currently offers such a program for Addyi, and what its dollar caps and fill limits are, is a fact that changes over time and was not independently verified for this draft. Patients should check the manufacturer's official site directly and confirm program terms before the first fill, since these programs are updated periodically and past figures are not a reliable guide to current terms.

Is compounded flibanserin legal in New York?

Pharmacies registered under Section 503A of the Federal Food, Drug, and Cosmetic Act may compound a medication for an individual patient based on a valid, patient-specific prescription, and this framework applies to flibanserin as it does to other approved drugs, subject to USP compounding standards (FDA compounding overview: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies). New York additionally regulates pharmacy practice through its own State Board of Pharmacy licensing and inspection requirements. This draft does not have a verified citation for a specific New York regulation number, so that detail has been removed; readers and prescribers should confirm current New York-specific compounding rules directly with the New York State Board of Pharmacy rather than relying on a cited regulation number that cannot be independently confirmed here.

One point of established federal policy is worth stating plainly: the FDA's REMS requirement for the brand product does not automatically extend to a compounded version dispensed by a 503A pharmacy under its own prescription, because REMS applies to the approved product and its authorized distribution chain. This does not remove the clinical obligation to counsel patients on the alcohol interaction, since the active ingredient and its pharmacology are identical regardless of who compounds it. Prescribers who choose to write for a compounded version should still document the same alcohol and CYP3A4 counseling that REMS requires for the brand product, and should confirm the receiving pharmacy's current state registration before sending the prescription.

Compounded medications are generally not reimbursed by insurance, so any cost advantage of compounding is primarily a cash-pay consideration, and specific compounding pharmacy prices are too variable and too easily out of date to state as fact here.

Can a New York clinician prescribe Addyi by telehealth?

Telehealth prescribing of controlled and non-controlled prescription medications is broadly permitted in New York when the prescriber holds a New York medical license and follows applicable federal and state requirements, and there is nothing in flibanserin's REMS structure that requires an in-person visit; REMS enrollment and patient counseling can occur during a video visit. New York has telehealth payment parity requirements affecting commercial insurers, though the exact statute citation and current scope of that parity requirement should be verified against the New York Department of Financial Services or Department of Health rather than assumed from a prior draft, since insurance law citations and their application change.

What the clinical trial evidence shows, and its limits

Flibanserin's approval rested on Phase 3, randomized, placebo-controlled trials in premenopausal women with generalized acquired HSDD, commonly referred to in FDA and journal literature as the BEGONIA, VIOLET, and DAISY trials. These trials reported an increase in satisfying sexual events and a reduction in HSDD-related distress scores compared with placebo over roughly 24 weeks, alongside a meaningfully higher rate of dropout for adverse events such as dizziness, somnolence, nausea, and fatigue compared with placebo. The magnitude of benefit reported across the program has been characterized in FDA review materials as modest in absolute terms. This draft does not carry forward specific numeric point estimates (exact events-per-28-days figures or exact distress-scale point differences) because the underlying identifiers available at the time of writing could not be independently confirmed against the correct paper, and a wrong citation is worse than a general one. Readers who need exact trial numbers for a prior authorization appeal or clinical decision should pull the current FDA-approved label and the primary trial publications directly rather than relying on a secondhand figure.

The mechanism is centrally acting rather than hormonal or vascular: flibanserin acts on serotonin and dopamine receptor activity in the brain rather than on genital blood flow, which is why effect, when present, builds gradually over weeks of nightly dosing rather than appearing acutely.

Evidence boundary: what is established, what is not

Established: FDA approval for premenopausal HSDD, REMS requirement, boxed alcohol warning, brand-only market status as of this writing, general federal permission for 503A compounding of approved drug substances, and general willingness of Medicaid and commercial plans to cover FDA-approved indications subject to formulary rules that change over time.

Plausible but not verified for this draft: the specific New York Medicaid prior authorization workflow and timeline, specific commercial insurer names and tier placements in New York, the existence and current terms of a manufacturer savings program, specific compounded and brand cash prices in New York pharmacies, and a specific New York regulation citation for pharmacy compounding oversight.

Not established from the material available here: any claim that a specific dollar figure represents the current 2026 New York price for brand or compounded flibanserin. Prices for brand specialty drugs and coupon-based cash prices change frequently enough that a number published in an article is not a reliable substitute for checking at the pharmacy counter.

When to seek in-person or urgent evaluation instead

Flibanserin is not appropriate for postmenopausal HSDD, for HSDD not meeting the generalized-acquired pattern studied in trials, or for patients with ongoing alcohol use disorder or liver impairment, given the alcohol and hepatic metabolism concerns tied to the boxed warning. A patient who experiences fainting, severe dizziness, or very low blood pressure after a dose, particularly after alcohol, needs urgent medical evaluation rather than waiting for a routine follow-up. Anyone considering flibanserin should have an individualized discussion with a licensed prescriber about diagnosis, alternatives such as counseling-based approaches, and whether the modest average benefit seen in trials is likely to be worth the interaction risk profile for them specifically; this page cannot substitute for that individualized assessment.

Verification checklist: stable facts versus facts you must recheck

Use this before relying on anything in a cost article about Addyi, including this one.

Federal and clinical facts that rarely change quickly (verify once, then trust for months to years):

• FDA approval status and indication (premenopausal HSDD), check the FDA label page directly
• REMS enrollment requirement for the brand product and its purpose (alcohol interaction)
• Boxed warning content (alcohol, CYP3A4 inhibitors, hypotension/syncope)
• Whether a generic flibanserin tablet has been FDA-approved
• General federal 503A compounding framework and its patient-specific-prescription requirement

Facts that are date-sensitive and must be rechecked at the time of use:

• Brand list price and pharmacy cash price
• Whether a manufacturer copay card exists, and its dollar cap, fill limit, and government-insurance exclusions
• Which specific New York commercial insurers cover flibanserin, on what tier, and under what step-therapy rules
• New York Medicaid's current prior authorization criteria and expected processing time
• Which named 503A pharmacies in New York currently compound flibanserin, their current registration status with the New York State Board of Pharmacy, and their current price
• Any state telehealth payment-parity statute citation and its current scope

How to verify each date-sensitive item:

• Call the specific pharmacy for cash price on the day of fill
• Call the specific insurance plan's member services line or check its online formulary tool for tier and prior authorization status
• Check the manufacturer's official site for current savings program terms
• Check the New York State Board of Pharmacy license verification tool for a compounding pharmacy's current registration
• Check eMedNY's current clinical policy pages for New York Medicaid prior authorization criteria

References

1. U.S. Food and Drug Administration. Addyi (flibanserin) approval history and REMS program. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526
2. U.S. Food and Drug Administration. Human drug compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
3. American College of Obstetricians and Gynecologists. Clinical guidance on female sexual dysfunction. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/01/female-sexual-dysfunction